ArticlePharmaceutics2020
Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO).
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 100 citations in OpenAlex.
- Deferoxamine-coated mesoporous silica nanoparticles sustainably reduce iron overload in HepG2 cells. A protein corona study on plasma from hemochromatotic mice.Drug delivery and translational research · 2026Article
- Biodegradable folate-mediated chitosan-CQD nanocarriers for targeted and stimuli-responsive cisplatin delivery in melanoma.Nanoscale advances · 2026Article
- Transmetalation in Cancer Pharmacology.International journal of molecular sciences · 2025Review
- Article
- Immobilization of the Proteolytic Fraction P1G10 fromMolecules (Basel, Switzerland) · 2025Article
- Selenium nanoparticle loaded on PVA/chitosan biofilm synthesized from orange peels: antimicrobial and antioxidant properties for plum preservation.BMC chemistry · 2025Article
- Exploring the potential of repurposed deferoxamine: bridging challenges and novel formulation opportunities.Nanomedicine (London, England) · 2025Review
- Article
- Hydrogel Composite Incorporating Deferoxamine-Loaded Gelatin-Based Microspheres Enhance Angiogenesis Ability of Dental Pulp Stem Cells.ACS omega · 2025Article
- Folic Acid-Conjugated Magnetic Oleoyl-Chitosan Nanoparticles for Controlled Release of Doxorubicin in Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2025Article
- Formulation Development of Natural Polymeric Nanoparticles, In Vitro Antiaging Evaluation, and Metabolite Profiling ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Chitosan Nanoparticle-EncapsulatedInternational journal of molecular sciences · 2025Article
- Formulating a TMEM176B blocker in chitosan nanoparticles uncouples its paradoxical roles in innate and adaptive antitumoral immunity.International journal of biological macromolecules · 2024Article
- Article
- Fabrication of PLA-Based Nanoneedle Patches Loaded with Transcutol-Modified Chitosan Nanoparticles for the Transdermal Delivery of Levofloxacin.Molecules (Basel, Switzerland) · 2024Article
- Drug Loading in Chitosan-Based Nanoparticles.Pharmaceutics · 2024Review
- Nanosponge for Iron Chelation and Efflux: A Ferroptosis-Inhibiting Approach for Myocardial Infarction Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Ferroptosis: a new hunter of hepatocellular carcinoma.Cell death discovery · 2024Review
- Exploring the Ocular Absorption Pathway of Fasudil Hydrochloride towards Developing a Nanoparticulate Formulation with Improved Performance.Pharmaceutics · 2024Article
- A Water-Soluble Chitosan Derivative for the Release of Bioactive Deferoxamine.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to develop chitosan (CS) nanoparticles (NPs) loaded with deferoxamine mesylate (DFO) for slow release of this iron-chelating drug. Drug nanoencapsulation was performed via ionic gelation of chitosan using sodium tripolyphosphate (TPP) as cross-linker. Nanoparticles with a size ranging between 150 and 400 nm were prepared for neat CS/TPP with a 2/1 molar ratio while their yield was directly dependent on the applied stirring rate during the preparation process. DFO at different content (20, 45 and 75 wt %) was encapsulated into these nanoparticles. We found that drug loading correlates with increasing DFO content while the entrapment efficiency has an opposite behavior due to the high solubility of DFO. Hydrogen-bonding between amino and hydroxyl groups of DFO with reactive groups of CS were detected using FT-IR spectroscopy while X-ray diffraction revealed that DFO was entrapped in amorphous form in the CS nanoparticles. DFO release is directly dependent on the content of loaded drug, while model analysis revealed that the release mechanism of DFO for the CS/TPP nanoparticles is by diffusion. Treatment of murine RAW 264.7 macrophages with nanoencapsulated DFO promoted an increased expression of transferrin receptor 1 (TfR1) mRNA, a typical homeostatic response to iron deficiency. These data provide preliminary evidence for release of pharmacologically active DFO from the chitosan nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.